Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts less than Nifty Microcap 250 and 5.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Windlas Biotech reported consolidated FY25 revenue from operations of Rs. 7,598.78 million, up about 20.4% from Rs. 6,309.56 million in FY24. Profit for the year grew modestly to Rs. 609.94 million (from Rs. 581.87 million, ~4.8% rise), while basic EPS improved to Rs. 29.19 vs Rs. 27.97. Q4 standalone revenue came in at Rs. 2,027.05 million, and the board has recommended a dividend of Rs. 5.80 per share (116% on face value of Rs. 5). The joint venture USpharma Windlas LLC ceased to exist from July 12, 2024. The statutory auditors S S Kothari Mehta & Co. LLP issued an unmodified opinion on both standalone and consolidated results.
Strong top-line growth of over 20% signals healthy business expansion, though muted profit growth (~5%) and a sharp drop in operating cash flow (Rs. 681.87M vs Rs. 1,089.60M) may temper investor enthusiasm. The Rs. 5.80 dividend and new ESOP plan are positive shareholder-friendly actions.